ViroPharma Inc. (VPHM) lost a bid for a court order temporarily blocking U.S. Food and Drug Administration marketing approval of generic forms of its biggest-selling drug, the antibiotic Vancocin. U.S. District Judge Ellen Segal Huvelle in Washington yesterday denied the company’s bid for injunctive relief in a 42-page ruling, saying ViroPharma failed to show it was likely to prevail on its claim the government decision was arbitrary or that the restraint would be in the public interest. “ViroPharma is evaluating potential legal options,” the company said today in a U.S. Securities and Exchange Commission filing disclosing Huvelle’s decision.
